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Summary
Background B-type natriuretic peptide (BNP) is a biomarker commonly used in diagnosing and assessing prognosis 
in heart failure patients. Its concentration can be elevated in various conditions associated with excessive heart wall 
stretch including atrial fibrillation and obstructive sleep apnoea (OSA). The aim of the study was to assess if BNP 
levels in atrial fibrillation patients are associated with the value of apnoea-hypopnea index (AHI).
Material and methods Study population were consecutive patients with atrial fibrillation, who underwent over-
night sleep study, and had blood taken for BNP concentration assessment. Subsequently, patients were divided into 
group according to AHI: Group I (< 5/h), Group II (5–15/h), and Group III (> 15/h). 
Results: Analysis covered 158 patients (males, 64.6%; mean age, 58.3 ± 9.2 years). 83 (52.5%) patients had AHI  
< 5/h, Group II consisted of 44 (27.9%), and Group III of 31 (19.6%) patients. Mean BMI and neck circumference 
rose with AHI value severity. BMI was as follows 28.7 ± 4.3, 30.7 ± 4.7, and 31.8 ± 5.2 kg/m2 (p for trend < 0.01), 
while neck circumference was 39.2 ± 3.5, 41.5 ± 3.9, and 41.2 ± 3.2 cm, (p for trend = 0.001) for Group I, II, and 
III respectively. BNP concentration was the lowest in Group I (53.0 ± 57.0 pg/mL), in middle ranges in Group II 
(69.2 ± 89.9 pg/mL), and the highest in patients with AHI > 15 (104.0 ± 150.8 pg/mL; p for trend = 0.03). 
Conclusions Majority of patients with atrial fibrillation have AHI < 5/h and these generally have lower BMI, and 
neck circumference. Patients who have AHI exceeding ≥ 5/h BNP levels tend to be elevated, and its values rise along 
with AHI.
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Background
Physicians constantly seek to find non-invasive, 
widely applicable screening and diagnostic methods. 
Hopes in this field are associated with a use of various 
biomarkers. Myoglobin, CK-MB (creatine kinase — 
MB), D-dimer, or especially troponins have been ex-
cessively studied, and had shown to be a useful clin-
ical tool, predictive for prognosis in various clinical 
conditions [1–4]. Today we almost cannot imagine 
clinical practice without biomarkers, like troponin 
in diagnosis of myocardial infarction, or D-dimer in 
ruling out pulmonary embolism, and next biomark-
ers still are undergoing excessive studies for their clin-
ical utility [5, 6]. B-type natriuretic peptide (BNP) 
and its N-terminal prohormone (NT-proBNP) are 
currently widely used in diagnosing and predicting 
long-term prognosis in heart failure and myocar-
dial infarction patients [7, 8]. BNP is produced in 
response to non-specific pressure overload of heart 
chambers, and therefore is a marker, found to be ele-
vated not only in heart failure, but also in other con-
arterial hypertension 2015, vol. 19, no. 4
180 www.ah.viamedica.pl
ditions associated with raise in intracardiac pressure 
such as arterial and pulmonary hypertension, valvular 
heart disease, atrial fibrillation, and even non-cardiac 
disease including pulmonary and renal disorders [9]. 
For some of the conditions mentioned above BNP 
will have limited utility in diagnostics, but as a pre-
dictor of heart involvement, therefore its remodelling 
and long-term outcome, BNP levels will be crucial. 
This applies especially to situations where number of 
conditions influencing heart haemodynamics coexists 
in one patient. Those conditions include i.e. atrial 
fibrillation and repetitive apnoea and hypopnoea epi-
sodes associated with obstructive sleep apnoea (OSA). 
The aim of the study was to establish if alterations 
in BNP profile in atrial fibrillation patients are asso-
ciated with the number of apnoea and hypopnoea 
episodes measured in apnoea-hypopnoea index (AHI).
Material and methods
Study population
The study protocol was approved by the Regional 
Ethics Committee and a written informed consent 
was obtained from every patient. Study population 
consisted of 163 consecutive patients hospitalized 
due to persistent or paroxysmal atrial fibrillation in 
a tertiary, Cardiology Department of a high-volume 
University Teaching Hospital. Primary indication 
for the hospitalization was pre-qualification for fu-
ture ablation for atrial fibrillation, in patients with at 
least one episode of the arrhythmia documented in 
a 24-hour Holter ECG monitoring during 6 months 
prior to the enrolment. We included in the study 
patients with atrial fibrillation documented in at least 
one 24-hour ECG Holter examination performed in 
6 months prior to the enrolment, who gave written 
informed consent. Patients with diagnosed heart fail-
ure or with clinical signs of heart failure in the initial 
examination, at the age of < 18 or ≥ 75 years, who 
underwent ablation for atrial fibrillation in the past, 
suffered from myocardial infarction, or stroke within 
last 6 months, with untreated significant hyper- or 
hypothyroidism, or currently undergoing treatment 
with continuous positive airway pressure were exclud-
ed from the study. According to the study protocol, 
apart from medical examination standard for atrial 
fibrillation, all patients underwent an over-night sleep 
study and had their BNP level measured.
Atrial fibrillation was defined as paroxysmal or 
persistent according to 2010 and 2012 guidelines of 
the European Society of Cardiology. Paroxysmal AF 
was defined as a self-terminating, usually within 48 h, 
which may continue for up to 7 days. Persistent AF 
was defined when AF episode either lasted longer than 
7 days or required termination by cardioversion, either 
with drugs or by direct current cardioversion [10, 11].
Sleep study
During the night following admission all patients un-
derwent an overnight polygraphy sleep study using 
a  portable device for diagnosing of sleep disorders 
(Embletta X30; Flaga, Reykjavik, Iceland), a  level 
3 sleep monitoring tool (according to the Europe-
an Respiratory Society and the European Society of 
Hypertension recommendations for sleep-disordered 
breathing management in cardiac patients), with 
> 4 channels including channels to detect respira-
tory movements or respiratory effort, airflow, heart 
rate, ECG, and oxygen saturation [12]. Every study 
was evaluated and scored manually by an experienced 
physician qualified in sleep medicine, according to the 
recommendations of the American Academy of Sleep 
Medicine [13]. Definition of apnoea was a cessation 
of airflow lasting ≥ 10 seconds, while hypopnea was 
defined as a recognizable transient reduction (but not 
complete cessation) of breathing for 10 seconds or 
longer with a reduction in air flow amplitude of more 
than 30% associated with following oxygen desatura-
tion of ≥ 3%. Total desaturation time was calculated 
basing on time period during which blood oxygen 
saturation was < 90%. All patients were also screened 
for symptoms of excessive daytime sleepiness using 
the Epworth Sleepiness Scale, with a  cut-off value 
for diagnosis of > 10 points. Elevated AHI value was 
considered ≥ 15 per hour irrespectively of the daytime 
symptoms. Patients were also divided into groups ac-
cording to the AHI value: to the group with AHI < 5 
per hour (Group I), AHI between 5 and 15 per hour 
(Group II) and AHI of > 15 per hour (Group III).
BNP analysis
BNP was measured in a 10 mL whole venous blood 
sample taken in the morning in supine position, to 
a  tube containing EDTA. Blood samples were im-
mediately analysed using Triage® BNP Test (Biosite 
Diagnostics, La Jolla, CA, USA). Triage® BNP Test is 
a  commercially available fluorescence immunoassay 
for the BNP quantification. It is a portable kit designed 
for quick, bedside BNP analysis. It has been validated 
in in vitro, as well as clinical studies, with an assay 
analytical sensitivity of less than 1.4 pmol/L [14, 15]. 
Manufacturer provided cut-off point suggestive of pa-
tients with congestive heart failure is > 100 pg/mL.
Statistical analysis
Continuous data are presented as mean ± stan-
dard deviation (SD) and were compared using the 
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Mann-Whitney test or Student’s  t-test. Categorical 
variables were compared using either the Chi-square 
or Fisher exact tests. A p value of less than 0.05 was 
considered statistically significant, whereas the con-
fidence intervals (CI) were 95%. A one-way analysis 
of variance was used to assess the impact of OSA se-
verity according to AHI on the BNP levels. Statistical 
analyses were performed using SAS statistical software 
version 8.02 (SAS Institute, Inc., Cary, NC, USA).
Results
Final analysis covered 158 patients (males, 64.6%; 
mean age, 58.3 ± 9.2 years), 3 patients were excluded 
from the study due to central sleep apnoea. In two cas-
es quality of polygraphy results and/or BNP measure-
ment was insufficient for further analysis (Figure 1). 
In the study population mean body mass index (BMI) 
meeting criteria for overweight was noticeable (29.9 
± 4.8 kg/m2). Patients also had large neck and waist 
circumference (40.2 ± 3.7 cm and 110.7 ± 81.6 cm, 
respectively). General co-morbidity in the study 
population was not high, except for hypertension, 
which was present in 74.1% and dyslipidaemia in 
59.5% of participants. Despite high prevalence of 
diagnosed hypertension, mean systolic and diastolic 
blood pressure (SBP and DBP) values on admission 
were 132.9 ± 16.6 mm Hg and 81.0 ± 11.4 mm Hg, 
respectively (Table I).
Figure 1. Study design
Table I. Baseline characteristics of the study population 
Parameter Mean ± SD or n(%)
Male sex; n(%) 102 (64.6%)
Age (years) 58.3 ± 9.2
Height [cm] 171.9 ± 10.1
Weight [kg] 88.3 ± 16.1
Body Mass Index [kg/m2] 29.9 ± 4.8
Neck circumference [cm] 40.2 ± 3.7
Waist circumference [cm] 110.7 ± 81.6
SBP [mm Hg] 132.9 ± 16.6
DBP [mm Hg] 81.0 ± 11.4
HR (beats per min) 74.1 ± 14.6
Prior myocardial infarction; n(%) 15 (9.5%)
Diabetes mellitus; n(%) 10 (6.3%)
Hypertension; n(%) 117 (74.1%)
Gout; n(%) 8 (5.1%)
Smoking; n(%) 17 (10.8%)
Alcohol consumption; n(%) 15 (9.5%)
Prior stroke; n(%) 16 (10.1%)
Peptic ulcer disease; n(%) 21 (13.3%)
Dyslipidaemia; n(%) 94 (59.5%)
Thyroid disease; n(%) 41 (25.9%)
Family history of CVD; n(%) 61 (38.6%)
Paroxysmal AF; n(%) 110 (69.9%)
BNP [pg/mL] 67.5 ± 92.9
SD — standard deviation, SBP — systolic blood pressure, DBP — diastolic blood pressure, HR — he-
art rate, CVD — cardiovascular disease, AF — atrial fibrillation, BNP — B-type natriuretic peptide
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Table II. Comparison of patients with and without obstructive sleep apnoea (OSA)
Parameter; mean ± SD or n(%) OSA (AHI ≥ 15/h)  
(n = 32)
No OSA (AHI < 15/h)  
(n = 126)
p value
AHI (per hour) 24.4 ± 10.1 4.5 ± 3.7 —
Lowest SpO2 (%) 79.7 ± 7.3 85.5 ± 5.4 < 0.0001
Male sex; n(%) 20 (62.5%) 82 (65.1%) 0.95
Age (years) 60.3 ± 7.3 57.8 ± 9.5 0.19
Height [cm] 172.7 ± 11.1 171.5 ± 9.9 0.61
Weight [kg] 94.5 ± 14.2 86.7 ± 16.2 0.01
Body Mass Index [kg/m2] 31.8 ± 5.1 29.4 ± 4.6 0.008
Neck circumference [cm] 41.1 ± 3.2 40.0 ± 3.8 0.14
Waist circumference [cm] 109.0 ± 10.9 103.1 ± 12.4 0.02
SBP [mm Hg] 133.9 ± 17.3 132.6 ± 16.5 0.71
DBP [mm Hg] 81.3 ± 13.2 80.9 ± 11.0 0.87
HR (beats per min) 75.5 ± 13.9 73.7 ± 14.8 0.53
Prior MI; n(%) 4 (12.5%) 11 (8.7%) 0.76
Diabetes mellitus; n(%) 4 (12.5%) 6 (4.8%) 0.23
Hypertension; n(%) 26 (81.3%) 91 (72.2%) 0.42
Gout; n(%) 0 (0.0%) 8 (6.3%) 0.31
Smoking; n(%) 2 (6.3%) 15 (11.9%) 0.55
Alcohol consumption; n(%) 6 (18.8%) 9 (7.1%) 0.1
Prior stroke; n(%) 4 (12.4%) 12 (9.5%) 0.86
Dyslipidaemia; n(%) 21 (65.6%) 73 (57.9%) 0.56
Thyroid disease; n(%) 6 (18.8%) 35 (27.8%) 0.42
Family history of CVD; n(%) 13 (40.6%) 48 (38.1%) 0.92
BNP [pg/mL] 101.8 ± 148.8 58.7 ± 70.3 0.04
SD — standard deviation; OSA — obstructive sleep apnoea; Lowest SpO2 — lowest registered blood oxygen saturation; SBP — systolic blood pressure; DBP — diastolic blood pressure; HR — heart rate; MI — my-
ocardial infarction; CVD — cardiovascular disease; AF — atrial fibrillation; BNP — B-type natriuretic peptide
Sleep study results revealed that elevated AHI valu- 
 es (≥ 15 per hour) were present in 20.3% of the 
study population. Patients with the elevated number 
of sleep disturbance episodes were more likely to 
have higher BMI (31.8 ± 5.1 vs. 29.4 ± 4.6 kg/m2; 
p = 0.008), and waist circumference (109.0 ± 10.9 vs. 
103.1 ± 12.4 cm; p=0.02). No significant differences 
were noticed regarding prevalence of co-morbidities, 
including hypertension, dyslipidaemia, diabetes, and 
history of vascular events. Parameters of the sleep 
study results showed that mean AHI in group with 
AHI ≥ 15 per hour was 24.4 ± 10.1 per hour, and 
4.5 ± 3.7 per hours in the other group. BNP levels 
were markedly higher in patients with AHI ≥ 15 
per hour (101.8 ± 148.8 vs. 58.7 ± 70.3 pg/mL; 
p = 0.04) (Table II). Symptoms of excessive day-time 
sleepiness were present in approximately 36.8% of 
patients with elevated AHI. 
Dividing patients into groups with AHI < 5 per 
hour (Group I), AHI between 5 and 15 per hour 
(Group II) and AHI of > 15 per hour (Group III) 
showed additional differences presented in detail in 
Table III. Group I consisted of 83 (52.5%) patients, 
Group II of 44 (27.9%) patients, and Group III of 
31 (19.6%) patients. As predicted, a trend towards 
worst oxymetry parameters with rising AHI values 
was noticeable. Mean AHI for Group I was 2.2 ± 1.4 
per hour, 9.1 ± 2.7 per hour for Group II, and 24.6 
± 10.2 per hour for Group III. Mean blood oxygen 
saturation was 94.2 ± 1.8 vs. 93.1 ± 1.5 vs. 93.4 ± 
1.8% (p for trend < 0.01), total percent time in de-
saturation was 2.5 ± 9.2 vs. 4.6 ± 7.1 vs. 7.7 ± 9.3% 
(p for trend 0.03), and lowest registered saturation 
was 86.4 ± 5.5 vs. 83.3 ± 4.9 vs. 79.9 ± 7.4, respec-
tively (p for trend < 0.001).
Other significant differences were noticed in terms 
of anthropometric features. Mean weight, BMI and 
neck circumference also rose with AHI values. Mean 
weight was equal 84.2 ± 15.2, 91.4 ± 17.0, and 95.0 
± 14.1 kg for Group I, Group II, and Group III 
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Table III. Differences between the groups according to obstructive sleep apnoea (OSA) severity
Parameter; mean ± SD or n(%) Non-OSA
AHI < 5/h (n = 83)
Mild OSA
AHI 5–15/h (n = 44)





AHI (per hour) 2.2 ± 1.4 9.1 ± 2.7 24.6 ±10.2 –
Mean SpO2 (%) 94.2 ± 1.8 93.1 ± 1.5 93.4 ± 1.8 < 0.01
Total desaturation time [min] 8.6 ± 29.1 18.2 ± 28.1 31.2 ± 35.0 < 0.01
Lowest SpO2 (%) 86.4 ± 5.5 83.3 ± 4.9 79.9 ± 7.4 < 0.001
Male sex; n(%) 47 (56.6%) 35 (79.5%) 20 (64.5%) 0.16
Age (years) 57.5 ± 10.4 58.6 ± 7.7 60.1 ± 7.4 0.37
Height [cm] 171.1 ± 10.7 172.5 ± 8.6 173.2 ± 10.9 0.54
Weight [kg] 84.2 ± 15.2 91.4 ± 17.0 95.0 ± 14.1 < 0.01
Body Mass Index [kg/m2] 28.7 ± 4.3 30.7 ± 4.7 31.8 ± 5.2 < 0.01
Neck circumference [cm] 39.2 ± 3.5 41.5 ± 3.9 41.2 ± 3.2 0.001
Waist circumference [cm] 112.6 ± 111.6 108.0 ± 11.7 109.4 ± 10.8 0.95
SBP [mm Hg] 132.6 ± 16.3 133.1 ± 17.1 133.3 ± 17.3 0.98
DBP [mm Hg] 79.7 ± 10.6 83.3 ± 11.2 81.0 ± 13.3 0.24
HR (beats per min) 72.7 ± 12.7 75.3 ± 18.1 76.0 ± 13.9 0.46
Prior MI; n(%) 8 (9.6%) 3 (6.8%) 4 (12.9%) 0.75
Diabetes mellitus; n(%) 4 (4.8%) 2 (4.5%) 4 (12.9%) 0.17
Hypertension; n(%) 58 (69.9%) 34 (77.3%) 25 (80.6%) 0.20
Gout; n(%) 4 (4.8%) 4 (9.1%) 0 (0.0%) 0.53
Smoking; n(%) 11 (13.3%) 4 (9.1%) 2 (6.5%) 0.26
Alcohol consumption; n(%) 5 (6.0%) 4 (9.1%) 6 (19.4%) 0.04
Prior stroke; n(%) 8 (9.6%) 4 (9.1%) 4 (12.9%) 0.67
Peptic ulcer disease; n(%) 11 (13.3%) 9 (20.5%) 1 (3.2%) 0.36
Dyslipidaemia; n(%) 50 (60.2%) 24 (54.5%) 20 (64.5%) 0.85
Thyroid disease; n(%) 24 (28.9%) 12 (27.3%) 5 (16.1%) 0.20
Family history of CVD; n(%) 33 (39.8%) 15 (34.1%) 13 (41.9%) 0.81
BNP [pg/mL] 53.0 ± 57.0 69.2 ± 89.9 104.0 ± 150.8 0.03
No OSA — patients with apnoea-hypopnoea < 5 per hour
Mild OSA — patients with apnoea-hypopnoea index 5–15 per hour
Severe OSA — patients with apnoea-hypopnea index > 15 per hour
SD — standard deviation; OSA — obstructive sleep apnoea; Lowest SpO2 — lowest registered blood oxygen saturation; Total desaturation time — time of blood oxygen saturation < 90%; SBP — systolic blood pressu-
re; DBP — diastolic blood pressure; HR — heart rate; MI — myocardial infarction; CVD — cardiovascular disease; AF — atrial fibrillation; BNP — B-type natriuretic peptide
Figure 2. Association between body mass index, B-type natriuretic 
peptide and obstructive sleep apnea severity
patients respectively (p for trend < 0.01). BMI for 
respective groups was as follows 28.7 ± 4.3, 30.7 ± 
4.7, and 31.8 ± 5.2 kg/m2 (p for trend < 0.01), while 
neck circumference was 39.2 ± 3.5, 41.5 ± 3.9, and 
41.2 ± 3.2 cm, respectively (p for trend = 0.001).
BNP also showed positive correlation with AHI 
values. Its concentration was the lowest in Group 
I  (53.0 ± 57.0 pg/mL), in middle value ranges in 
mild Group II (69.2 ± 89.9 pg/mL), and the highest 
in Group III (104.0 ± 150.8 pg/mL; p for trend = 
0.03) (Figure 2).
Applying different thresholds AHI (including 
forming groups with AHI 15–30 per hour and ≥ 
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30 per hour) did not show for the observed trend to 
continue. After exceeding cut off point of AHI > 15, 
mean BNP concentrations for rising AHI groups did 
not show to be statistically higher. 
Discussion
Both, atrial fibrillation and sleep disturbances, in-
cluding OSA are diseases highly prevalent in the 
general population, with prevalence estimated to be 
approximately 2% and rising with age, even up to 
15% in 80-year-old for atrial fibrillation, and preva - 
lence of OSA being 24% and 9% for men and wom-
en respectively [16–18]. OSA prevalence in the gen-
eral population of atrial fibrillation patients is esti-
mated to be between from 32 and 49% [19]. Due 
to their common pathophysiology, and often coexis-
tence, atrial fibrillation and OSA were even previous-
ly described to be a part of a clinical syndrome [20].
In atrial fibrillation patients, as well as in the 
general population, occurrence of sleep disordered 
breathing associated with apnoeas and hypopneas, 
is correlated with factors such as older age, higher 
BMI, and therefore larger waist circumference and 
neck circumference [19]. In present study, prevalence 
of patients with elevated AHI values and factors 
associated with their occurrence were similar to data 
in the literature. We showed that, AHI values of ≥ 5 
per hour were present in 47.5% of the study group, 
and associated with older age and higher BMI than 
in patients without the sleep-disordered breathing.
Currently, there are no biomarkers specific only 
for atrial fibrillation, but many different substances 
were tested for their clinical utility in this condition 
[21]. Cardiac troponins which are specific for myo-
cardial necrosis, and are released during injury to the 
cardiac muscle have also been studied in settings of 
atrial fibrillation condition. Troponins in circulating 
blood of atrial fibrillation patients were shown to be 
a predictor of worse outcome. Patients with higher 
troponin concentration are more likely to have ma-
jor cardiac and/or cerebrovascular events and have 
higher mortality rates [22, 23]. Other biomarkers 
like inflammatory markers and various adipokines 
have also been studied. High levels of C-reactive pro-
tein (CRP), the most widely used biomarker linked 
to inflammation, demonstrated to be predictive for 
increased risk for developing atrial fibrillation [24]. 
Further studies also revealed its association with com-
posite end-point of stroke and death, or composite of 
ischaemic stroke, myocardial infarction and vascular 
death [25, 26]. Markers of thrombosis and fibrinoly-
sis, including D-dimer and b-thromboglobulin, were 
predictors of hypercoagulability, and therefore their 
elevated levels correlated with the risk of thrombo-
embolism (including stroke and systemic thrombo-
embolism) [27]. Also platelet function parameters 
and markers of endothelial dysfunction were also 
altered in patients with atrial fibrillation [21]. Con-
flicting data on the association between the BNP 
concentrations and atrial fibrillation may be found in 
the literature, but most of the studies seem to show 
that elevated BNP levels are associated with higher 
risk of new-onset atrial fibrillation and NT-proBNP 
is predictive of thromboembolic risk, stroke and car-
diovascular mortality [23, 28, 29].
Although limited data is available, studies show 
different results regarding BNP levels and its clinical 
utility in patients with sleep disordered-breathing. 
Most of the studies base on small samples of symp-
tomatic OSA patients. Many of available data focus 
mostly on BNP variations during the nighttime. One 
of the studies showed nocturnal variations in BNP 
levels, with a peak between 2:00 and 6:00 AM in pa-
tients with OSA, which was reduced, if patient used 
continuous positive airway pressure (CPAP) therapy 
[30]. In other studies, conducted in women with 
OSA, a correlation between sleep disordered breath-
ing severity and BNP levels was found [31, 32]. 
Contrary, other investigators reported no alterations 
of BNP profile in patients with OSA, and also found 
a lack of its correlation with OSA treatment [33, 34]. 
In present study, we showed that the disease severity 
measured by AHI was associated with increase in 
BNP level. Patients with AHI > 15 per hour, here 
defined as severe OSA, during the nighttime under-
go constant, repetitive disruptions in ventilation fol-
lowed by microarousals, much more frequently than 
patients with lower AHI (mild OSA) or free from the 
disease. To understand this correlation we must refer 
to the fact, that short-lasting hypoxia is not associated 
with a rise in BNP, whereas repeating, sustaining epi-
sodes are [35]. Therefore, like shown in present study, 
only patients with high AHI, therefore longer time 
of hypoxia are likely to present elevated BNP levels.
Another interesting finding from the present study 
refers to association of BNP, BMI, and obstructive 
apnoea-hypopnoea episodes specific for OSA. OSA 
prevalence is well known to be associated with in-
creasing body mass, and BMI. In morbidly obese pa-
tients the disease is found to be approximately 90% 
[36]. Obesity not only exacerbates OSA, by easing 
the airways obstruction, but OSA itself promotes 
obesity. Daytime sleepiness associated with OSA pre-
disposes patients to experience reduction physical 
activity, worse physical performance, and worsening 
of energy metabolism [20, 37].
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Contrary, despite obvious increased hemodynam-
ic overload in obese patients, studies show that BNP 
levels in this group are likely to be lower than in the 
non-obese population. Large population data, com-
ing in example from studies like Framingham study 
show negative correlation with this natriuretic pep-
tide and body mass [38]. Similar trends are observed 
also in patients with cardiovascular disease, includ-
ing heart failure [39]. This association is not fully 
resolved, but few hypotheses have been proposed to 
explain the issue [40]. First of all, increased peripher-
al clearance of natriuretic peptides has been noticed 
in obese patients. It is due to an increased expression 
of C-type natriuretic peptide receptor in fat tissue. 
The receptor plays role in degradation of various 
peptides, including BNP. Other hypothesis refers 
to gonadal hormones. Level of oestrogens is altered 
in overweight and obese patients, while oestrogens/ 
/androgens circulating ratio is one of the factors re-
sponsible for BNP production and excretion. Other 
theories refer the role of adipokines, salt retention, 
and ectopic fat deposits in cardiac muscle tissue [39]. 
Unfortunately, up to date all remain speculative and 
unexplained.
In the present study, contrary to abovementioned 
finding BNP levels rose along with the AHI score. 
It can be explained by the fact, that AHI parameters 
were closely associated also with BMI. To simpli-
fy, the fatter the patient was, the higher the AHI, 
and the higher the AHI, the more likely the patient 
was to experience persistent hypoxia, and haemody-
namic overload in heart chambers. Consequences 
of repetitive apnoeas and hypopnoeas, include au-
tonomic dysregulation, elevated sympathetic tone, 
oxidative stresses, endothelial dysfunction, atrial 
stretch caused, and increased intrathoracic pressure, 
and contribute to heart overload (in the same man-
ner promoting atrial fibrillation) [20]. It was proven, 
that apnoeas and hypopnoeas associated with OSA 
deteriorate function of the ventricles and causes in-
creased heart wall stress [41]. We can hypothesize 
that number of apnoea-hypopnoea episodes and its 
BNP production promoting effect overcomes the 
suppression coming from fat deposits, which is espe-
cially visible in patients with atrial fibrillation, who 
are already predisposed to have altered intracardiac 
haemodynamics.
Conclusions
Episodes of OSA are highly prevalent in patients 
with atrial fibrillation. In patients who have AHI 
values exceeding ≥ 15 per hour BNP concentrations 
are higher compared to the patients who have AHI 
< 15 per hour. In this group of patients, elevated 
BNP levels indicate that number of sleep disordered 
breathing episodes may be associated with extensive 
heart wall stretch. Also, BNP levels rise along with 
AHI values, irrespectively for suppressing effect of 
elevated BMI. 
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